Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Post by Accountprinceon Jun 21, 2022 10:43am
241 Views
Post# 34771095

AGM Disclosures

AGM DisclosuresHope some of the posters here took the time to listen to the AGM presentation.  Some gems in the presentation that is available in SEDAR - I encourage each of you to get it and read it:

EAA and PMX - Baxter and Spectral working closely on pre-launch activities suggests Baxter much more enthused now.  Kellum did add verbally to "exceeding expectations" that results are "greatly" - so putting it together you'd have "greatly exceeding expectations".  The presentation also disclosed that they have submitted to the FDA for a "breakthrough designation".  I am drawing a conclusion and path - how about the rest of you?

Dialco - the presentation talks about developing a "strategic partnership" to bring in funds directly.  Kellum said progressing but discussions preclude disclosure of details at this time.  That implies the discussions are more advanced that the "developing" stage.  Sam Amory very impressive speaking and with what he's achieved in a very short period of time.  Looks like Dialco has the goods and people to get there.  Seto repeated his "when not if" for DIMI in terms of FDA approval.

This one didn't leave me feeling same old...same old...just the opposite


<< Previous
Bullboard Posts
Next >>